Lecanemab has not been as widely tested in Black patients.
Almost anyone can take this quick test for Alzheimer’s without even going to the doctor. It’s a terrible idea.
Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.
Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease.
This recognition is a testament to Dr. Klein’s expertise and the high-quality headache care we deliver at Abington Neurological Associates.
On March 22, Weisman and his fellow advisers voted unanimously that the drug was ‘reasonably likely’ to prove beneficial, paving the way for the agency to approve it Tuesday.
Tofersen, an injection treatment for a rare form of ALS, has been approved under the accelerated approval pathway.
The committee convened to discuss tofersen, an experimental injection for treatment of ALS.
Leqembi significantly reduces progression of memory loss in those with Alzheimer’s disease by about 30%.
Blood tests for Alzheimer’s biomarkers will be a powerful tool in determining who will benefit from a drug.